RECALLS AND SAFETY ALERTS INCREASED MORTALITY IN LIVER TRANSPLANT PATIENTS TREATED WITH RAPAMUNE
August 10, 2009
FDA is alerting healthcare professionals that stable liver transplant patients may have an increased risk of death if they are switched from an immunosuppressive regimen based on a calcineurin inhibitor (CNI) to sirolimus. Sirolimus, which is market...
Full Story Below
Rapid Response
Free Case Evaluation
The Help You Need,
When You Need it Most
More from FDA News Directory
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
lawyercen
